Efficacy and tolerance of combination of Cytidine 5 ' monophosphate (CMP) and Uridine-5 ' Triphosphate Trisodium (UTP) in patients with diabetic neuropathy: results of a study conducted in Dakar-Senegal

Abstract

Diabetic neuropathy is the earliest and most common chronic complication of diabetes. There are 
numerous therapeutic methods, but most of them present a problem of efficacy and tolerance. NUCLEO 
CMP FORTE ® is a combination of nucleotides (Cytidine 5'- Monophosphate Disodium and Uridine -5' 
Triphosphate Trisodium). Several preclinical studies have demonstrated the effect the combination of CMP 
and UTP in the regeneration of the myelin sheath and nerve cells. The aim of this study was to evaluate the 
efficacy and safety of the combination of CMP and UTP in the treatment of diabetic neuropathy. In a 
prospective study, we conducted a 3- month clinical trial of the combination of CMP and UTP in 75 patients 
with diabetic neuropathy. The methods of investigation were clinical (Visual Analogous Scale, Neuropathy 
Disability Scale and Neuropathy Symptom Scale), electrophysiological (electromyography) and biochemical 
(liver and kidney function tests). The patients (68) had a mean age of 56 years. They were mostly female 
(72%), had diabetes 2 (95.6%) and all types of neuropathic pain. The medication had improved the sensory 
disorders as well as the intensity of pain in diabetic neuropathy patients. There was also a significant 
increase in sensory conduction velocity in the right median nerve and left sciatic nerves during the 
electromyographic tests. No clinical or biological side effects have been noted. The combination of CMP 
and UTP is useful in the treatment of diabetic neuropathy. We recommended its use for diabetic patients 
with neuropathy.